Real&Best (R&B) is a game-changing gene therapy company that is revolutionizing the field of rAAV design and production leading to innovative medicines. Established in Chengdu China in 2018, R&B is committed to original research and cost-efficient production. The aim of the company is to make rAAV gene therapies, from bench to bedside, “Faster, Better and cost-effective (accessible)”. A range of AAV platforms, based on bioinformatics and AI technology, have been developed, covering all necessary elements for rAAV design and large-scale production including novel promoters, therapeutic genes and capsids, greatly reducing the time from R&D to clinical trials.

Our cutting-edge production platform is a breakthrough in the industry, as it overcomes the bottleneck of large-scale rAAV production while significantly reduces production costs, making gene therapy more accessible than ever.

R&B has completed the full industry chain layout for original rAAV gene therapies including drug development, production platform, and clinical translation. The company has a team of outstanding scientists, clinicians and entrepreneurs. Founder Professor Dong Biao has more than fifteen years of experience in rAAV research, achieving breakthroughs in drug design and large-scale production. Core team members have extensive experience, covering all aspects of drug development, namely, drug design, preclinical research, CMC development, GMP production, regulatory filings, clinical trials, and operational management.